Merck’s antiviral no better than placebo in cutting hospitalization and death, trials find
According to the results of a pair of large clinical trials, Merck’s experimental antiviral pill failed to lower the risks of COVID-19 hospitalization and death among adults at higher risk from the disease. The company, in partnership with Ridgeback Biotherapeutics. conducted two real-world evidence studies evaluating the drug, molnupiravir, In a trial of more than 25,000 people by researchers at Oxford University, the oral antiviral helped shorten the recovery time of acute infection but showed no substantial benefit compared to taking a placebo in most serious adverse COVID-related events. In a separate study conducted in Israel, real-world data showed that while molnupiravir reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above, “no evidence of benefit was found in younger adults ages 40 to 64 years.” SF Chronicle
molnupiravir was sold in 30 countries
VitaminDWiki Virus pages with PILL in title (4 as of Oct 2022)
This list is automatically updated